Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis
about
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritisOpen label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolongJuvenile Idiopathic Arthritis: Diagnosis and TreatmentSoluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuitsProtective effects of C-type natriuretic peptide on linear growth and articular cartilage integrity in a mouse model of inflammatory arthritisSoluble cytokine receptors: basic immunology and clinical applications.ADAM-17: the enzyme that does it all.Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver.Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls.Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients.Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis.The therapeutic potential of interleukin-6 hyperagonists and antagonists.Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis.Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.Emerging role of anti-tumor necrosis factor therapy in rheumatic diseasesOsteoporosis in the rheumatic disease patient.Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis).Biologic therapies for juvenile arthritisSuccessful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.The development and assessment of biological treatments for children.Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.Developments in the treatment of juvenile arthritis.Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.Interleukin-6: structure-function relationships.The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.Interleukin 6 is required for the development of collagen-induced arthritisEngineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007).Biologic treatments for systemic rheumatic diseasesInterleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.Interleukin and interleukin receptor diversity: role of alternative splicing.Guidance on using tocilizumab for juvenile idiopathic arthritis.Neurophysiology of arthritis pain.Tocilizumab for treating juvenile idiopathic arthritis.IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.
P2860
Q24805600-369E01EA-039B-437E-B900-5A07975B1386Q24812856-DCB4FF23-11D0-4F78-BC20-7C541A441DEFQ28079246-03F2267B-3C72-4C91-AF31-D669151F71ACQ28728941-FE9F6080-7B80-48B6-89BA-8D46B64082ACQ33667772-CEBF1652-C042-4BA3-99CB-D4D7C2AB8EAFQ33688222-D1B6F3B4-D155-4CED-A166-F0E7BE3B1AF5Q33737421-79EACF2B-0A24-48B6-9B46-5C717416BE99Q33889571-51C7636B-FE95-40EE-975B-76E5A434A579Q33918736-3AE1ADDB-9C72-4ECD-8F9A-7C9A9B026155Q33920812-C20A3B2E-5EF1-4B03-8BE2-707C939A5266Q34152981-A9184AE1-7A4D-41C5-A04B-35D9AFE5F1F0Q34430168-9EAA9EC4-951C-49EF-B2EC-F5693312A01CQ34449130-E5B45F4C-2EB0-40AB-A585-3B6AC20A1FC3Q34646212-322EFD5D-44A3-43BA-8CA4-708E17BB2B6AQ34704820-FCE595F1-8106-4DC5-9440-276F62356375Q34731307-EF61B2C4-86E7-4C67-AE23-6BDA4ED73C16Q34986976-54DDEA9E-0BF5-4B4E-BC9F-9E9D20DD73C7Q35040784-EE84A867-1BFC-4784-A8AC-8BE79E302A47Q35070925-637FFD8B-3F8E-4166-83C9-8AE963926816Q35084293-D704C788-76EA-4326-8096-F811A68CB1E5Q35135936-765C7229-305E-42F0-896C-45008995C1D6Q35609892-CF97E3D4-F856-44A2-B8B9-CF6E1DCA25B4Q35814399-A1BA8C14-1760-4D9C-B116-DFBC317BAA75Q35953233-91B1C8D7-89E6-42D1-B32C-BCE61B97BAB6Q36280356-AB5AABD0-BA17-453A-8FF8-CBD42EB964FEQ36366332-41D67764-317A-4610-9477-768029EB7698Q36400353-26213B8F-A3C7-4E35-B516-4EB9315C933CQ36801817-8B6D561E-0212-4F0D-9EE5-C5E246F37620Q36967869-1AADF46B-F19B-4BF6-8F39-341C1AE9A61BQ37087438-0DD62EF4-394D-4A00-9F95-2EF144F70251Q37363276-CBEE84A2-CF91-4DEB-971D-065E566950C1Q37373492-BB0C19F1-53F0-4C7C-BCFE-F7F2B94A8371Q37680986-74904D57-09BF-4CFB-AC88-172BD17A1019Q37877601-8C3CEE1A-FED3-43D1-A31B-D44A30A99EE2Q38051258-5800C24C-9140-48AA-AD71-06F7BD84CECBQ38723988-17038457-51AE-4EB4-B4E2-F3FFF928BFBDQ39079705-D1AEBC87-54B8-4CCF-A19A-5418C32ECDD7Q39573539-1A01B2EC-DCC2-4F76-9CEF-71EFFD26C48AQ39761819-CFFE3890-616E-49FD-B126-08B5C8524D39Q40163734-3BE8F1EA-7083-437E-B3EE-711184A2CE40
P2860
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Serum soluble interleukin 6 (I ...... juvenile rheumatoid arthritis
@en
type
label
Serum soluble interleukin 6 (I ...... juvenile rheumatoid arthritis
@en
prefLabel
Serum soluble interleukin 6 (I ...... juvenile rheumatoid arthritis
@en
P2093
P2860
P356
P1476
Serum soluble interleukin 6 (I ...... juvenile rheumatoid arthritis
@en
P2093
P2860
P304
P356
10.1172/JCI117206
P407
P577
1994-05-01T00:00:00Z